Endometrial cancer (EC) is the most common female pelvic malignancy with a life-time risk of 4% (1). It is usually diagnosed at an early stage and has a good prognosis accounting for only 2% of cancer-related deaths (1, 2). The most common age at the time of diagnosis is between 65 and 75 years with a mean age of 69 years (3). However, young women may also be affected by EC. Specifically, around 10% of women diagnosed with EC are <50 years of age with a range of 7 to 20% reported in the literature (1-4). This subset of women with EC is characterized by an elevated risk of synchronous ovarian cancer and an increased prevalence of hereditary non-polyposis colon cancer syndrome (HNPCC). This has important consequences for the management, prognosis, and genetic counselling of young women with EC.
proposed that the disseminating cells of SEOC may be restricted to physically accessible and microenvironment-compatible sites, i.e. the endometrium and the ovary, with a limited capacity for further dissemination (13) . Others have confirmed a high rate of monoclonality among SEOC cases (14) .
In case of SEOC, ovarian involvement may be interpreted as metastatic disease or synchronous primary ovarian cancer based on histology and immunohistochemistry. Immunohistochemistry is usually applied to distinguish between an ovarian metastasis of EC and primary ovarian cancer. Endometrioid adenocarcinomas of the endometrium typically express estrogen and progesterone receptors. Other frequently altered genes are KRAS, PTEN, and β-catenin (15) . A subset progresses into high-grade carcinoma which is accompanied by loss of receptor expression and accumulation of TP53 mutations. Low-grade serous carcinoma of the ovary is also associated with KRAS mutations, but in contrast to EC typically expresses mutated BRAF (16) . Another useful marker to differentiate between EC and ovarian cancer is PAX-8, because primary ovarian cancer but not EC metastases, express PAX-8 (17) . The exact differential diagnosis between an ovarian metastasis and a second primary ovarian cancer, however, is difficult. In the series of Walsh et al., for example, the majority of cases (23/26 [88%]) were classified as synchronous primaries and only 3/26 (12%) were considered ovarian metastases of EC (12) . To the contrary, Oranratanaphan et al. diagnosed synchronous primary ovarian cancer in 14/63 (22%) and ovarian metastases in 49/63 (78%) cases (4) . Akbayir et al. described a 16/28 (57%) versus 12/28 (43%) distribution, respectively (7) . This discrepancy in the literature underscores the difficulty of distinguishing between ovarian metastasis of EC and a second primary ovarian cancer, especially in cases of two endometrioid adenocarcinoma histologies. These difficulties in the differential diagnosis of SEOC are, however, important, because an exact distinction between ovarian metastasis and primary ovarian cancer has prognostic and therapeutic implications. For example, Oranratanaphan et al. reported a 5-year disease-free survival rate of 64% compared to 41% in the synchronous and metastatic groups, respectively and the 5-year overall survival rate was 92% versus 48% (4). In addition, patients with EC and metastatic disease in the adnexae would be classified as FIGO stage III cases and thus be eligible for adjuvant platinum-based chemotherapy with or without radiotherapy. On the other hand, patients with an EC and a second primary FIGO stage 1A ovarian cancer would be adequately treated with clinical follow-up alone (18) .
Hereditary non-polyposis colon cancer syndrome (HNPCC) is an autosomal dominant genetic syndrome conferring a 85 to 90% life-time risk of colon cancer, a 40-60% life-time risk of EC, and a 6 to 12% life-time risk of ovarian cancer (19, 20) . In unselected populations of women with EC, HNPCC is found in 9 to 11% of women (21) . Young women with EC, especially those with SEOC, may even have a higher prevalence of HNPCC, although the exact rate of HNPCC in this subpopulation of women with EC is unknown.
To highlight the clinical and genetic characteristics, management, and prognosis of young women with SEOC, we report the case of a 45-year-old woman with histologically verified endometrioid adenocarcinoma of the endometrium and synchronous endometrioid ovarian cancer. In addition, we present a systematic review of the literature with case reports and case series of young women with SEOC and discuss common characteristics shared by these women.
Case Report
We present the case of a 45-year-old woman with histologically verified endometrioid adenocarcinoma of the endometrium and synchronous endometrioid ovarian cancer. In November 2016, the patient was diagnosed with therapyresistant menstrual bleeding disorder. Dilatation and curettage was performed and histology revealed a moderately differentiated endometrioid adenocarcinoma of the endometrium. In December 2016, she underwent total laparoscopic hysterectomy and bilateral salpingooophorectomy. Intraoperative assessment of the depth of infiltration revealed an International Federation of Gynecology and Obstetrics (FIGO) stage 1B EC with tumor invasion into the outer third of the myometrium. Subsequently, staging surgery with laparoscopic pelvic lymphadenectomy was performed in the same session. Intraoperative frozen section analysis of the pelvic lymph nodes showed no evidence of pelvic lymph node metastases. The intraoperative and postoperative course of the patient was uncomplicated. The final histological report confirmed a moderately differentiated endometrioid adenocarcinoma of the endometrium (FIGO pT1B, G2, R0 without lymphovascular space invasion). In addition, a synchronous, bilateral, moderately differentiated endometrioid carcinoma of the ovaries (pT1A, G2, R0) was found. Figure 1 shows hematoxylin-eosin stains of the endometrial and ovarian tumor specimens. Figure 2 shows immunohistochemical studies with estrogen receptor, progesterone receptor, and PAX-8 expression for both tumor specimens. The patient had no family history of colon cancer, EC, breast, or ovarian cancer. HNPCC assessment by immunohistochemistry was performed and showed no microsatellite instability in the MSH2, MSH6, MLH1, and PMS2 proteins (Figure 3 ). No adjuvant therapy was administered. Follow-up with regular clinical gynecological examinations was recommended. The patient is well and alive without evidence of recurrent disease at the time of this report. Studies not reporting on women with SEOC and studies reporting on women with benign ovarian tumors were excluded. Therefore, in summary, 63 studies were retrieved in full and analyzed for this review. Among these studies, we found 16 case reports, 8 retrospective cases series, 38 retrospective cohort studies, and one prospective cohort study. Figure 4 shows a diagram of the literature search. Table I 
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. Immunohistochemical stains of an endometrial cancer specimen demonstrating the expression of estrogen receptors (A) progesterone receptors (B) an ovarian cancer specimen demonstrating the expression of estrogen receptors (C), progesterone receptors (D) and PAX-8 (E). Black bars represent 50 μm.
characteristics and outcomes of patients with SEOC described in all 63 studies. In summary, 2904 women with SEOC were reported with 1035 (36%) of them being premenopausal or <50 years of age. In 28 of 63 studies, the number of EC cases, among which women with SEOC were identified, was reported. The proportion of women with SEOC among all reported EC cases was 842/23498 (3%) and the proportion of young women with SEOC among all reported EC cases was 261/23498 (1%). Among women with SEOC, most cases of EC and ovarian cancer were early stage tumors with 72% of EC cases classified as FIGO stage I disease and 70% of ovarian cancer cases classified as FIGO stage I disease. The predominant histologic type of SEOC was endometrioid adenocarcinoma in both the endometrium and the ovary. This combination was found in 694/1163 (60%) of SEOC cases.
The largest cohort of young women with SEOC was published by Williams et al. (5) . In this population-based analysis of the SEER database, the authors identified 530 (39%) women <50 years of age among a population of 1355 SEOC cases. They compared the prognosis of women with SEOC and women diagnosed with ovarian cancer alone and found a 25% reduction in the risk of death. Interestingly, this effect was not only seen in early stage cases, but also in women with late stage cases suggesting a favorable prognosis for SEOC independent of tumor stage. In this study, no separate analysis of young women with SEOC regarding prognosis and stage distribution was performed. The five largest monocentric retrospective cohort studies with more detailed clinical data investigated between 157 (47) and 84 (30) SEOC cases. In these studies, the proportion of young women with SEOC varied considerably with 10% (9/93) (39), 17% (21/123) (61), 23% (36/157) (47), 48% (30/63) (4), and 51% (43/84) (30) .
The only prospective cohort study recruiting women with SEOC was a Gynecologic Oncology Group (GOG) study published by Zaino et al. (29) . In this study, 74 women with SEOC confined to the pelvis were prospectively enrolled, thus ensuring homogenous clinicopathologic characteristics and treatment regimens. A high proportion of women had microscopic spread of tumor in the pelvis or abdomen ANTICANCER RESEARCH 37: 969-978 (2017) 972 Figure 
Immunohistochemical stains of an endometrial cancer specimen demonstrating the expression of MLH-1 (A), PMS-2 (B), MSH-2 (C) and MSH-6 (D). Black bars represent 50 μm.
(23/74, 31%). Despite this fact, the probability of recurrence after 5 years was only 15% and the overall probability of surviving 5 and 10 years was 86% and 80%, respectively. The presence of microscopic metastasis in the pelvis or abdomen, however, discriminated two groups of patients with strikingly different probabilities of recurrence. Specifically, the 5-year recurrence rate was 27% for patients with compared to 10% for patients with microscopic metastases in the pelvis or abdomen.
The bulk of studies identified in this systematic review were retrospective cohort studies with <50 patients with SEOC (6-10, 12, 22, 24, 25, 28, 31, 34, 37, 38, 42, 44, 49, 51, 52, 55, 56, 58, 59, 61, 62, 65, 67-71) , cases series of individual patients (13, 23, 35, 36, 43, 45, 66, 73) , and case reports (26, 27, 32, 33, 41, 46, 50, 53, 54, 57, 60, 63, 64, 72, 74, 75) . As expected, the heterogeneity among these studies with low numbers of patients was high. However, as shown in Table I , most patients had early stage disease of the endometrial and ovarian cancers and the predominant histology was synchronous endometrioid adenocarcinoma.
HNPCC analysis was performed in only 15/2904 young women with SEOC. Microsatellite instability and subsequent mutations in mismatch repair genes were identified among 6/15 (40%) of tumors analyzed (Table II) . Mutations in the MSH2, MSH6, MLH1, and PMS2 genes were identified in 3, 1, 3, and 1 cases, respectively. Recurrence-free survival time and overall survival time were reported for 7 and 77 young women with SEOC, respectively. The mean recurrence-free survival time was 1.9 (min 0.2, max 3) years and the mean overall survival time was 4.0 (min 0.2, max 22.1) years.
Discussion
In this case report and review of the literature, we describe a young woman with synchronous endometrioid adenocarcinoma of the endometrium and both ovaries. HNPCC analysis showed no microsatellite instability in MSH2, MSH6, MLH1, and PMS2. We identified 2904 cases of women with SEOC in the literature with 1035 (36%) of them being premenopausal or <50 years of age. HNPCC analysis was only reported for 15 of these women with 6/15 (40%) demonstrating microsatellite instability and subsequent mutations in mismatch repair genes compatible with HNPCC. These data demonstrate that young women with EC have a high risk of synchronous ovarian cancer and a high proportion of HNPCC. Thus, in young women with EC, bilateral salpingo-oophorectomy or careful histological assessment of both ovaries are recommended in order to confirm or rule out SEOC. HNPCC testing should be offered to all women with SEOC.
Our data are comparable with previously reported studies on young women with SEOC. Based on our analysis, 3% of women with EC are young, i.e. premenopausal or <50 years of age, and a third of these women have SEOC. In accordance, our pooled analysis of the literature identified a proportion of 36% of young women among all women diagnosed with SEOC. This is compatible with the data of Williams et al. (5) . They performed a population-based analysis of 1355 women with SEOC and identified 530 (39%) cases of premenopausal women (5) . Together, these data show that young women with EC have a surprisingly high risk of SEOC. When managing young women with EC, treating physicians should be aware that a third of them will have synchronous ovarian cancer. It seems therefore reasonable to perform bilateral salpingo-oophorectomy or at least careful histological assessment of both ovaries by targeted biopsies in order to confirm or rule out SEOC. (43) 2009 CS 70* 9 (13%) 0/13 --7/2 9 (13%) Gungor ( The typical histology of SEOC is endometrioid adenocarcinoma of both the endometrial and the ovarian tumors, which has been described in up to 70% of cases (12) . Our analysis confirms that the majority of SEOC cases are diagnosed at an early stage and display synchronous endometrioid adenocarcinomas in both endometrium and ovary. Specifically, we found that 72% of EC cases and 70% of ovarian cancer cases were classified as FIGO stage I (13) . Others have confirmed these findings by subjecting cancer tissue from five SEOC cases to whole-exome massively parallel sequencing, demonstrating that the endometrial and ovarian tumor cells displayed strikingly similar repertoires of somatic mutations and gene copy number alterations in all investigated cases (14) . These data suggest that in women with SEOC, the endometrium and the ovary represent microenvironmentcompatible sites with preferential dissemination of tumor cells.
The prognosis of women with SEOC is good based on a high proportion of early stage cases and favorable histologies. In addition to these favorable clinicapthologic characteristics, the prognosis of women with SEOC seems to be better than that of women with single ovarian cancer, independent of tumor stage (5) . This may be due to genetically-based restrictions of tumor dissemination in women with SEOC (13) . In our analysis of survival data in the literature, the mean recurrence-free survival time of young women with SEOC was 1.9 years and the mean overall survival time was 4.0 years. These survival data underscore that young women with SEOC still have a compromised outcome and guidelinecompatible treatment regarding surgical staging and adjuvant treatment should be applied. In order to optimize the longterm outcome of young women with SEOC, the high risk of HNPCC should be recognized. Our data underscore the strong association of SEOC and HNPCC in young women. Specifically, we found that microsatellite instability and subsequent mutations in mismatch repair genes compatible with HNPCC are present in 40% of women. This is significantly higher than what has been reported in unselected populations of women with EC, where HNPCC is found in 9-11% of women (21) . Therefore, despite the low number of SEOC patients in the literature analyzed for HNPCC mutations, HNPCC screening in all women with SEOC seems reasonable.
In conclusion, we found that young women with EC have a high risk of synchronous ovarian cancer and a have high risk of HNPCC. Thus, in young women with EC, bilateral salpingooophorectomy or careful histological assessment of both ovaries are recommended in order to confirm or rule out SEOC. HNPCC testing should be offered to all women with SEOC.
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